| Dr John F Mega, MD | |
|
1120 Kanawha Blvd E, Charleston, WV 25301-2400 | |
| (304) 344-3457 | |
| (304) 344-3480 |
| Full Name | Dr John F Mega |
|---|---|
| Gender | Male |
| Speciality | Radiology - Diagnostic Radiology |
| Location | 1120 Kanawha Blvd E, Charleston, West Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154325793 | NPI | - | NPPES |
| G14623 | Other | WV | BRICKSTREET INSURANCE |
| 0120703000 | Medicaid | WV | |
| 0130753 | Other | WV | UMWA |
| 0171077 | Medicaid | OH | |
| 14193 | Other | WV | CARELINK & CARELINK PEIA |
| 14175 | Medicaid | WV | |
| 64942006 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 18171 (West Virginia) | Primary |
| Entity Name | Radiology Imaging Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063400729 PECOS PAC ID: 2466342803 Enrollment ID: O20040318000719 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.
A new, implantable device to control heart failure is showing promising results in the first trial to determine safety and effectiveness in patients, according to lead researcher Dr. William Abraham of The Ohio State University Wexner Medical Center.
Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.
› Verified 9 days ago
| Entity Name | East Central Florida Outpatient Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245271675 PECOS PAC ID: 9830175199 Enrollment ID: O20040628000215 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.
A new, implantable device to control heart failure is showing promising results in the first trial to determine safety and effectiveness in patients, according to lead researcher Dr. William Abraham of The Ohio State University Wexner Medical Center.
Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.
› Verified 9 days ago
| Entity Name | Inverness Medical Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093763591 PECOS PAC ID: 3870590672 Enrollment ID: O20061108000195 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.
A new, implantable device to control heart failure is showing promising results in the first trial to determine safety and effectiveness in patients, according to lead researcher Dr. William Abraham of The Ohio State University Wexner Medical Center.
Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John F Mega, MD Po Box 11137, Charleston, WV 25339-1137 Ph: (304) 344-3457 | Dr John F Mega, MD 1120 Kanawha Blvd E, Charleston, WV 25301-2400 Ph: (304) 344-3457 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.
Scientists have identified a genetic signature that is remarkably effective at predicting the prognosis of an aggressive liver cancer in children.
A new, implantable device to control heart failure is showing promising results in the first trial to determine safety and effectiveness in patients, according to lead researcher Dr. William Abraham of The Ohio State University Wexner Medical Center.
Researchers in the U.S. say that preliminary research has suggested that nicotine can prevent chemotherapy drugs such as taxol from killing lung cancer cells.
› Verified 9 days ago
Matthew W. Morris, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Dr. Mary H.l. Mcjunkin, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Ravindra K Gogineni, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1021 Quarrier St, Ste 301, Charleston, WV 25301 Phone: 304-343-4625 Fax: 304-343-4626 | |
Riad Al-asbahi, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1021 Quarrier St, Ste 301, Charleston, WV 25301 Phone: 304-343-4625 Fax: 304-343-4626 | |
Dr. Jennifer M. Smith, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 | |
Timothy Aaron Vanhoose, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1120 Kanawha Blvd E, Charleston, WV 25301 Phone: 304-344-3457 Fax: 304-344-3480 |